Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    Endoscopic Submucosal Dissection | ( Map: Florida, United States )

Multi-center Evaluation of the Clinical Utility of ESD in the Western Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02989818
Recruitment Status : Recruiting
First Posted : December 12, 2016
Last Update Posted : February 26, 2021
Sponsor:
Information provided by (Responsible Party):
University of Florida

Brief Summary:
The aim of this multi-center study is to prospectively document the clinical utility of ESD.

Condition or disease Intervention/treatment
Endoscopic Submucosal Dissection Other: Endoscopic Submucosal Dissection

Detailed Description:

Multi-center prospective data recording study. All patients will receive standard medical care and no experimental interventions will be performed.

All patients scheduled to undergo ESD at the University of Florida and participating centers as medically indicated will be considered for the study. Patients in whom ESD is considered as part of their standard medical care will be offered to participate in this study. The physician performing the procedure will also discuss the study with the subjects. If the patient agrees to participate, he or she will be given the informed consent form and allowed enough time to read it. Opportunity to ask questions will be provided. If the patient agrees to participate, he or she will sign the consent form and a copy will be provided. Data will be prospectively recorded according to the data collection form. ESD will be performed as medically indicated. The investigators from each respective center on this project will also be in charge of the medical care of the patients enrolled in the study. Follow-up will be carried out as medically indicated and no additional studies or clinic visits will be needed specifically for the purpose of this study.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Multi-center Prospective Evaluation of the Clinical Utility of Endoscopic Submucosal Dissection (ESD) in the Western Population
Actual Study Start Date : March 2016
Estimated Primary Completion Date : January 2026
Estimated Study Completion Date : January 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy

Group/Cohort Intervention/treatment
Lesion of the Gastrointestinal tract
Investigator will collect prospective data on the Endoscopic Submucosal dissection that is used as part of the subjects standard of care to remove the Gastrointestinal lesion
Other: Endoscopic Submucosal Dissection
This intervention is part of the subjects standard of care and is a method to remove the Gastrointestinal lesion.
Other Name: ESD




Primary Outcome Measures :
  1. Rate of en-bloc resection [ Time Frame: 3-4 hours ]
    An Excision of the targeted lesion in a single specimen


Secondary Outcome Measures :
  1. Rate of R0 resection [ Time Frame: 3-4 hours ]
    when all vertical and horizontal margins are negative

  2. Rate of R1 resection [ Time Frame: 3-4 hours ]
    complete resection with no grossly visible lesion defined by endoscopist but microscopically positive horizontal and /or vertical margins

  3. Curative resection [ Time Frame: 3-4 hours ]
    this will have the following: R0 resection, Well to moderately differentiated histology, Absence of Lymphovascular invasion, Absence of budding, Absence of invasion beyond superficial submucosa

  4. Rate of Adverse events with ESD [ Time Frame: 1 month ]
    Early (<48 hours) and late (>48 hours) adverse events defined based on previously established criteria by the American Society of Gastrointestinal Endoscopy (ASGE)

  5. Rate of complete remission of neoplasia [ Time Frame: 1 month ]
    Absence of a visible lesion and/or absence of the neoplastic lesion on biopsy specimens (histopathology) obtained from the ESD site on follow up evaluations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients scheduled to undergo ESD at the University of Florida and participating centers as medically indicated and part of their standard of care
Criteria

Inclusion Criteria:

  • a. Age 18 years or older.
  • b. Scheduled to undergo ESD as part of their standard of care.

Exclusion Criteria:

  • a. Any contraindication to performing endoscopy.
  • b. Participation in another research protocol that could interfere or influence the outcome measures of the present study.
  • c. Patient is unable/unwilling to provide informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02989818


Contacts
Layout table for location contacts
Contact: Peter Draganov, MD 352-273-9472 peter.draganov@medicine.ufl.edu

Locations
Layout table for location information
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32610
Contact: Peter Draganov, MD    352-273-9472    peter.draganov@medicine.ufl.edu   
Principal Investigator: Peter Draganov, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
University of Florida
Investigators
Layout table for investigator information
Principal Investigator: Peter Draganov, MD University of Florida
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT02989818    
Other Study ID Numbers: IRB201600246
First Posted: December 12, 2016    Key Record Dates
Last Update Posted: February 26, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided